FERM domain containing 7Genealiases: NYS · NYS1 · XIPAN
Q-omics provides the consensus-scored FRMD7 profile across patient tissues and cancer cell-line models. FRMD7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FRMD7 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FRMD7 RNA expression shows 10,766 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, KIRC, and TGCT as cancer lineages where FRMD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMD7 survival associations across molecular data types. FRMD7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMD7 RNA expression–survival associations across cancer types. High FRMD7 expression shows unfavorable associations in STAD, CHOL, ACC, OV and LGG, but favorable associations in UVM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for FRMD7 RNA expression.
This table summarizes FRMD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FRMD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMD7 shows lower tumor expression in KIRC, KIRP and UCEC and higher tumor expression in COAD, BRCA and LUSC. The KIRC box plot shows higher FRMD7 RNA expression in normal versus tumor tissue (log2 FC = −2.423, t-test p < 0.001).
This table shows molecular features associated with FRMD7 in patient tissues and cancer cell lines. In patient samples, FRMD7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
